Abstract
The aim of this study was to formulate and characterize Eudragit® L100 and Eudragit® L100-poly(lactic-co-glycolic acid) (PLGA) nanoparticles containing diclofenac sodium. Diclofenac generates severe adverse effects with risks of toxicity. Thus, nanoparticles were prepared to reduce these drawbacks in the present study. These nanoparticles were evaluated for surface morphology, particle size and size distribution, percentage drug entrapment, and in vitro drug release in pH 6.8. The prepared nanoparticles were almost spherical in shape, as determined by atomic force microscopy. The nanoparticles with varied size (241–274 nm) and 25.8–62% of entrapment efficiency were obtained. The nanoparticles formulations produced the release profiles with an initial burst effect in which diclofenac sodium release ranged between 38% and 47% within 4 h. The extent of drug release from Eudragit® L100 nanoparticles was up to 92% at 12 h. However, Eudragit®/PLGA nanoparticles showed an initial burst release followed by a slower sustained release. The cumulative release at 72 h was 56%, 69%, and 81% for Eudragit®/PLGA (20:80), Eudragit®/PLGA (30:70) and Eudragit®/PLGA (50:50) nanoparticles, respectively. The release profiles and encapsulation efficiencies depended on the amount of Eudragit in the blend. These data demonstrated the efficacy of these nanoparticles in sustaining the diclofenac sodium release profile.
Similar content being viewed by others
References
Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Contr Release. 2001;70(1–2):1–20.
Serda RE, Godin B, Blanco E, Chiappini C, Ferrari M. Multi-stage delivery nano-particle systems for therapeutic applications. Biochim Biophys Acta. 2010 (in press).
Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces. 2010;75(1):1–18.
Lai SK, Wang YY, Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev. 2009;61(2):158–71.
Galindo-Rodriguez SA, Allemann E, Fessi H, Doelker E. Polymeric nanoparticles for oral delivery of drugs and vaccines: a critical evaluation of in vivo studies. Crit Rev Ther Drug Carrier Syst. 2005;22(5):419–64.
Yamanaka YJ, Leong KW. Engineering strategies to enhance nanoparticle-mediated oral delivery. J Biomater Sci Polym Ed. 2008;19(12):1549–70.
Warner TD, Vojnovic I, Bishop-Bailey D, Mitchell JA. Influence of plasma protein on the potencies of inhibitors of cyclooxygenase-1 and -2. FASEB J. 2006;20(3):542–4.
Mitchell JA, Warner TD. Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy. Br J Pharmacol. 1999;128(6):1121–32.
Sena MM, Chaudhry ZF, Collins CH, Poppi RJ. Direct determination of diclofenac in pharmaceutical formulations containing B vitamins by using UV spectrophotometry and partial least squares regression. J Pharm Biomed Anal. 2004;36(4):743–9.
González M, Rieumont J, Dupeyron D, Perdomo I, Fernandez E, Abdón L, et al. Nanoencapsulation of acetyl salicylic acid within enteric polymer nanopaticles. Rev Adv Mater Sci. 2008;17:71–5.
Piao ZZ, Lee MK, Lee BJ. Colonic release and reduced intestinal tissue damage of coated tablets containing naproxen inclusion complex. Int J Pharm. 2008;350(1–2):205–11.
Moustafine RI, Margulis EB, Sibgatullina LF, Kemenova VA, Van den Mooter G. Comparative evaluation of interpolyelectrolyte complexes of chitosan with Eudragit L100 and Eudragit L100-55 as potential carriers for oral controlled drug delivery. Eur J Pharm Biopharm. 2008;70(1):215–25.
Saffari M, Shahbazi M, Ardestani MS. Formulation and in vitro evaluation of Eudragit L100® microspheres of piroxicam. Nat Precedings. 2008;1544(1):1–5.
Andrews GP, Jones DS, Diak OA, McCoy CP, Watts AB, McGinity JW. The manufacture and characterisation of hot-melt extruded enteric tablets. Eur J Pharm Biopharm. 2008;69(1):264–73.
Devarajan PV, Sonavane GS. Design and evaluation of pH modulated controlled release matrix systems for colon specific delivery of indomethacin. Pharmazie. 2007;63(10):736–42.
Devarajan PV, Sonavane GS. Preparation and in vitro/in vivo evaluation of gliclazide loaded Eudragit nanoparticles as sustained release carriers. Drug Dev Ind Pharm. 2007;33(2):101–11.
Rowe RC, Sheskey PJ, Owen SC. Handbook of pharmaceutical excipients. 5th ed. London: Pharmaceutical Press and American Pharmacists Association; 2006.
Mohamed F, van der Walle CF. Engineering biodegradable polyester particles with specific drug targeting and drug release properties. J Pharm Sci. 2008;97(1):71–87.
Dillen K, Bridts C, Van der Veken P, Cos P, Vandervoort J, Augustyns K, et al. Adhesion of PLGA or Eudragit/PLGA nanoparticles to staphylococcus and pseudomonas. Int J Pharm. 2008;349(1–2):234–40.
Jawahar N, Eagappanath T, Nagasamy V, Jubie S, Samanta MK. Preparation and characterisation of PLGA-nanoparticles containing an Anti-hypertensive agent. Int J Pharm Tech Res. 2009;1(2):390–3.
Song X, Zhao Y, Hou S, Xu F, Zhao R, He J, et al. Dual agents loaded PLGA nanoparticles: systematic study of particle size and drug entrapment efficiency. Eur J Pharm Biopharm. 2008;69(2):445–53.
Cetin M, Aktas Y, Vural I, Capan Y, Dogan LA, Duman M, et al. Preparation and in vitro evaluation of bFGF-loaded chitosan nanoparticles. Drug Deliv. 2007;14(8):525–9.
International Conference on Harmonization (ICH), Q2b: Validation of analytical procedures: methodology. US FDA Federal Register; 1997 (Vol. 62): p. 27463
Hombreiro Pérez M, Zinutti C, Lamprecht A, Ubrich N, Astier A, Hoffman M, et al. The preparation and evaluation of poly(epsilon-caprolactone) microparticles containing both a lipophilic and a hydrophilic drug. J Contr Release. 2000;65(3):429–38.
Cetin M, Capan Y, Vural I, Dogan AL, Guc D, Hincal AA, et al. Preparation and characterization of bFGF and BSA loaded microspheres. J Drug Deliv Sci Tech. 2005;15(5):371–5.
Mundargi RC, Srirangarajan S, Agnihotri SA, Patil SA, Ravindra S, Setty SB, et al. Development and evaluation of novel biodegradable microspheres based on poly(d, l-lactide-co-glycolide) and poly(epsilon-caprolactone) for controlled delivery of doxycycline in the treatment of human periodontal pocket: in vitro and in vivo studies. J Control Release. 2007;119(1):59–68.
D'Souza SS, DeLuca PP. Methods to assess in vitro drug release from injectable polymeric particulate systems. Pharm Res. 2006;23(3):460–74.
Kouchak M, Atyabi F. Ion exchange, an approach to prepare an oral floating drug delivery system for diclofenac. Iran J Pharm Res. 2004;2:93–7.
Tunçay M, Caliş S, Kaş HS, Ercan MT, Peksoy I, Hincal AA. Diclofenac sodium incorporated PLGA (50:50) microspheres: formulation considerations and in vitro/in vivo evaluation. Int J Pharm. 2000;195(1–2):179–88.
Kilic AC, Capan Y, Vural I, Gursoy RN, Dalkara T, Cuine A, et al. Preparation and characterization of PLGA nanospheres for the targeted delivery of NR2B-specific antisense oligonucleotides to the NMDA receptors in the brain. J Microencapsul. 2005;22(6):633–41.
Saxena V, Sadoqi M, Shao J. Indocyanine green-loaded biodegradable nanoparticles: preparation, physicochemical characterization and in vitro release. Int J Pharm. 2004;278(2):293–301.
Sahoo SK, Labhasetwar V. Nanoparticles interface: an important determinant in nanoparticle-mediated drug/gene delivery. In: Gupta RB, Kompella UB, editors. Nanoparticle technology for drug delivery. New York: Taylor & Francis Group; 2006. p. 139–54.
Bala I, Bhardwaj V, Hariharan S, Kharade SV, Roy N, Ravi Kumar MN. Sustained release nanoparticulate formulation containing antioxidant-ellagic acid as potential prophylaxis system for oral administration. J Drug Target. 2006;14(1):27–34.
Konan YN, Cerny R, Favet J, Berton M, Gurny R, Allémann E. Preparation and characterization of sterile sub-200 nm meso-tetra(4-hydroxylphenyl)porphyrin-loaded nanoparticles for photodynamic therapy. Eur J Pharm Biopharm. 2003;55(1):115–24.
Fattal E, Quaglia F, Gupta P, Brazeau G. Biodegradable microparticles for the development of less-painful and less-irritating parenterals. In: Gupta P, Brazeau G, editors. Injectable Drug Development: Techniques to Reduce Pain and Irritation. Informa Health Care; 1999. p. 355–78.
Wischke C, Schwendeman SP. Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles. Int J Pharm. 2008;364(2):298–327.
Choi HS, Seo SA, Khang G, Rhee JM, Lee HB. Preparation and characterization of fentanyl-loaded PLGA microspheres: in vitro release profiles. Int J Pharm. 2002;234(1–2):195–203.
Musumeci T, Ventura CA, Giannone I, Ruozi B, Montenegro L, Pignatello R, et al. PLA/PLGA nanoparticles for sustained release of docetaxel. Int J Pharm. 2006;325(1–2):172–9.
Lin SY, Chen KS, Teng HH, Li MJ. In vitro degradation and dissolution behaviours of microspheres prepared by three low molecular weight polyesters. J Microencapsul. 2000;17(5):577–86.
Dai J, Nagai T, Wang X, Zhang T, Meng M, Zhang Q. pH-sensitive nanoparticles for improving the oral bioavailability of cyclosporine A. Int J Pharm. 2004;280(1–2):229–40.
Al-Taani BM, Tashtoush BM. Effect of microenvironment pH of swellable and erodable buffered matrices on the release characteristics of diclofenac sodium. AAPS J Pharm Sci Tech. 2003;4(3):E43.
Basavaraj BV, Deveswaran R, Bharath S, Abraham S, Furtado S, Madhavan V. Hollow microspheres of diclofenac sodium—a gastroretentive controlled delivery system. Pak J Pharm Sci. 2008;21(4):451–4.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cetin, M., Atila, A. & Kadioglu, Y. Formulation and In vitro Characterization of Eudragit® L100 and Eudragit® L100-PLGA Nanoparticles Containing Diclofenac Sodium. AAPS PharmSciTech 11, 1250–1256 (2010). https://doi.org/10.1208/s12249-010-9489-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1208/s12249-010-9489-6